A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone

NCT05813665 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

146

Enrollment

INDUSTRY

Sponsor class

Conditions

Giant Cell Tumor of Bone

Interventions

DRUG: Narlumosbart
DRUG: Denosumab

Sponsor

Shanghai JMT-Bio Inc.